KYNB (Kyntra Bio) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KYNB Kyntra Bio Inc KYNB
53 GF Score
Price $7.08
GF Value $3.10
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kyntra Bio  (NAS:KYNB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kyntra Bio Cyclically Adjusted PB Ratio Related Terms


Kyntra Bio Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted PB Ratio Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.78 4.16 0.21 0.14 0.11

Kyntra Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.14 0.10 0.08 0.09

KYNB vs IGC, ATNM, NNVC: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted PB Ratio falls into.


KYNB
53GF Score
Kyntra Bio Inc KYNB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kyntra Bio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kyntra Bio's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.011/333.9520*333.9520
=-2.011

Current CPI (Jun. 2026) = 333.9520.

Kyntra Bio Quarterly Data

Book Value per Share CPI Adj_Book
201609 78.326 241.428 108.343
201612 68.762 241.432 95.113
201703 58.587 243.801 80.251
201706 87.844 244.955 119.759
201709 180.522 246.819 244.251
201712 165.985 246.524 224.850
201803 155.473 249.554 208.053
201806 152.882 251.989 202.609
201809 144.549 252.439 191.224
201812 154.646 251.233 205.564
201903 147.595 254.202 193.900
201906 186.622 256.143 243.312
201909 175.930 256.759 228.822
201912 152.698 256.974 198.440
202003 134.323 258.115 173.789
202006 115.026 257.797 149.005
202009 129.540 260.280 166.206
202012 120.693 260.474 154.740
202103 105.960 264.877 133.592
202106 75.546 271.696 92.856
202109 93.051 274.310 113.283
202112 61.669 278.802 73.868
202203 47.705 287.504 55.412
202206 33.005 296.311 37.198
202209 12.315 296.808 13.856
202212 -0.393 296.797 -0.442
202303 -7.474 301.836 -8.269
202306 -15.352 305.109 -16.803
202309 -29.287 307.789 -31.776
202312 -41.055 306.746 -44.696
202403 -46.785 312.332 -50.024
202406 -47.404 314.175 -50.388
202409 -50.040 315.301 -53.000
202412 -45.492 315.605 -48.137
202503 -43.280 319.799 -45.195
202506 -44.766 322.561 -46.347
202509 4.322 324.800 4.444
202512 1.106 324.054 1.140
202603 -2.295 330.213 -2.321
202606 -2.011 333.952 -2.011

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Kyntra Bio (KYNB) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.08 is trading 128.2% above its estimated GF Value™ of $3.10. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for KYNB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $3.10 vs. price of $7.08 (128.2% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the KYNB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
53GF Score

Get the complete analysis for KYNB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.08
Price
$3.10
GF Value